Flyer

Annals of Clinical and Laboratory Research

  • ISSN: 2386-5180
  • Journal h-index: 19
  • Journal CiteScore: 5.42
  • Journal Impact Factor: 4.64
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
+44 7460731551
Awards Nomination
It Medical Team Scan Code
PMC/PubMed Indexed Articles

Isolated Large Cell Calcifying Sertoli Cell Tumor in a Young Boy, not Associated with Peutz-Jeghers Syndrome or Carney Complex

Google Scholar citation report
Citations : 1577

Annals of Clinical and Laboratory Research received 1577 citations as per Google Scholar report

Flyer image
Annals of Clinical and Laboratory Research peer review process verified at publons
Flyer image
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Directory of Research Journal Indexing (DRJI)
  • Publons
  • Euro Pub
  • Google Scholar
  • SHERPA ROMEO
  • Secret Search Engine Labs
  • Zenodo
View More
Share This Page

Short Communication - (2023) Volume 11, Issue 6

The Role of Liquid Biopsies in Cancer Diagnosis: A Clinical Biochemistry Perspective

Roman Fiore*
 
Department of medical oncology, University of Rouen, France
 
*Correspondence: Roman Fiore, Department of medical oncology, University of Rouen, France, Email:

Received: 01-Nov-2023 Published: 27-Nov-2023, DOI: 10.36648/2386-5180.23.11.491

Introduction

Cancer, one of the leading causes of death worldwide, has long been a challenge for healthcare professionals. Traditional methods of cancer diagnosis often involve invasive procedures like tissue biopsies, which can be uncomfortable and carry certain risks [1,2]. However, recent advancements in clinical biochemistry have paved the way for a revolutionary approach: liquid biopsies. These non-invasive tests offer valuable insights into cancer detection, prognosis, and treatment monitoring, transforming the landscape of cancer diagnosis. This article explores the role of liquid biopsies in cancer diagnosis from a clinical biochemistry perspective [3].

Understanding Liquid Biopsies: Liquid biopsies involve the analysis of various biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes, present in bodily fluids like blood. These biomarkers carry genetic information about the tumor and can be detected and analyzed through advanced molecular techniques. Unlike traditional biopsies, liquid biopsies offer a less invasive and more accessible method of capturing vital information about the cancer's genetic makeup [4,5].

Early Detection and Prognosis: One of the significant advantages of liquid biopsies is their ability to detect cancer at an early stage. ctDNA, released by tumor cells into the bloodstream, carries genetic mutations specific to the cancerous growth. By analyzing ctDNA, clinicians can identify these mutations even before the physical symptoms manifest, enabling early intervention and improved outcomes [6].

Personalized Treatment Approaches: Liquid biopsies play a crucial role in advancing the field of personalized medicine. By analyzing the genetic mutations and alterations detected in ctDNA, clinicians can identify targeted therapies tailored to the patient's unique genetic profile. This precision medicine approach maximizes the effectiveness of treatments while minimizing side effects, leading to better patient outcomes and enhanced quality of life [7].

Monitoring Treatment Response: In addition to diagnosis and prognosis, liquid biopsies are instrumental in monitoring a patient's response to treatment. Traditional imaging techniques might not capture subtle changes in tumor size or progression, especially during targeted therapies. Liquid biopsies, on the other hand, provide a dynamic and real-time view of the cancer's genetic landscape. Monitoring ctDNA levels allows clinicians to assess the treatment's efficacy promptly. If the treatment proves ineffective, adjustments can be made swiftly, ensuring that patients receive the most suitable therapies throughout their cancer journey [8,9].

Challenges and Future Directions: While liquid biopsies hold immense promise, challenges such as standardization of testing methods, cost, and insurance coverage need to be addressed. Researchers and healthcare professionals are actively working to overcome these hurdles, aiming to make liquid biopsies a routine part of cancer diagnosis and management [10].

Conclusion

Liquid biopsies represent a groundbreaking advancement in cancer diagnosis, offering a comprehensive and non-invasive approach to understanding the disease. From early detection to personalized treatment strategies and real-time monitoring, these tests have the potential to revolutionize cancer care. As clinical biochemistry continues to evolve, the integration of liquid biopsies into routine practice holds the key to improving cancer outcomes and providing hope to patients and their families facing this challenging diagnosis.

References

  1. De Rubis G, Krishnan SR, Bebawy M (2019). Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol. Sci. 40(3):172-86.

    2. Indexed at, Google Scholar, Cross Ref

  2. Vaidyanathan R, Soon RH, Zhang P, Jiang K, Lim CT(2019) . Cancer diagnosis: From tumor to liquid biopsy and beyond. Lab on a Chip. 19(1):11-34.

    3. Indexed at, Google Scholar, Cross Ref

  3. Mader S, Pantel K (2017). Liquid biopsy: current status and future perspectives. Oncol Res Treat. 40(7-8):404-8.

    4. Indexed at, Google Scholar, Cross Ref

  4. Fernández-Lázaro D, García Hernández JL, García AC, Córdova Martínez A, Mielgo-Ayuso J, et al (2020). Liquid biopsy as novel tool in precision medicine: Origins, properties, identification and clinical perspective of cancer’s biomarkers. Diagnostics. 10(4):215.

    5. Indexed at, Google Scholar, Cross Ref

  5. Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, et al (2014). Liquid biopsies in lung cancer: The new ambrosia of researchers. Biochim Biophys Acta Rev Cancer. 1846(2):539-46.

    6. Indexed at, Google Scholar, Cross Ref

  6. Alix-Panabières C, Pantel K (2013). Circulating tumor cells: liquid biopsy of cancer. Clinical chemistry.;59(1):110-8.

    7. Indexed at, Google Scholar, Cross Ref

  7. Palmirotta R, Lovero D, Cafforio P, Felici C, Mannavola F, et al (2018). Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol.10:1758835918794630.

    8. Indexed at, Google Scholar, Cross Ref

  8. Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, et al (2019). How liquid biopsies can change clinical practice in oncology. Ann Oncol. 30(10):1580-90.

    9. Indexed at, Google Scholar, Cross Ref

  9. Kelley SO, Pantel K (2020). A new era in liquid biopsy: from genotype to phenotype. Clin Chem. 66(1):89-96.

    10. Indexed at, Google Scholar, Cross Ref

  10. Heitzer E, Ulz P, Geigl JB (2015). Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 61(1):112-23.

    11. Indexed at, Google Scholar, Cross Ref

Citation: Fiore R (2023) The Role of Liquid Biopsies in Cancer Diagnosis: A Clinical Biochemistry Perspective. Ann Clin Lab Res.Vol.11 No.6:491